U.S. markets close in 2 hours 29 minutes

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.45+0.12 (+1.34%)
As of 01:31PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close9.33
Bid9.44 x 1800
Ask9.45 x 2900
Day's Range9.33 - 9.58
52 Week Range8.42 - 12.40
Avg. Volume9,391,638
Market Cap11.316B
Beta (5Y Monthly)1.19
PE Ratio (TTM)5.47
EPS (TTM)1.73
Earnings DateMay 08, 2023 - May 12, 2023
Forward Dividend & Yield0.48 (5.22%)
Ex-Dividend DateMar 08, 2023
1y Target Est15.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
36% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for VTRS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Viatris Inc.
    Analyst Report: Viatris IncViatris Inc., based in Pennsylvania, is a specialty and generic drug company formed in 2020 through the combination of Pfizer's Upjohn business and Mylan N.V. The shares are a component of the S&P 500. The company has 37,000 employees.
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Motley Fool

    3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential

    Healthcare spinoffs aren't normally seen as companies with strong growth potential. More likely than not, spinoffs stem from a division of a company that, while possibly profitable, is seeing slower growth. Embecta (NASDAQ: EMBC.V), Viatris (NASDAQ: VTRS) and GE Healthcare Technologies (NASDAQ: GEHC) are three of the bigger healthcare spinoffs in recent years.

  • Motley Fool

    I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.

    How high of a dividend yield does a stock need to have to be considered a high-yield stock? Opinions vary. However, many investors would include any stock with a yield that's greater than that offered by 10-year U.

  • Motley Fool

    Pfizer Has Another Blockbuster on the Horizon, but That's Not All

    Over the past year, Pfizer (NYSE: PFE) made a series of acquisitions, even announcing at one point that it planned to remain "very active in deal-making." On March 13, Pfizer announced the planned blockbuster acquisition of cancer specialist Seagen (NASDAQ: SGEN) for a massive $43 billion in cash. This move, expected to close by year-end or early 2024, will likely improve Pfizer's prospects, and it is only the latest in a series of important and successful strategic decisions the company's management has made.